Novo Nordisk to enter phase 3 development in Alzheimer’s disease with oral semaglutide
Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer’s disease with 14 mg oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analogue semaglutide. The decision follows evaluation of GLP-1 data from preclinical models, real-world evidence studies, post-hoc analysis of data from large cardiovascular outcomes trials, as well as discussions with regulatory authorities.
Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 3,700 people with early Alzheimer’s disease. The programme is planned for initiation in the first half of 2021 and will investigate the efficacy and safety of once-daily oral semaglutide, compared to placebo. The expected main treatment period in the trials is around two years.
“As a company we aspire to address high unmet medical needs within serious chronic diseases, and we are therefore pleased to initiate phase 3 development of semaglutide within Alzheimer’s disease,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer at Novo Nordisk. “Alzheimer’s disease has been an area of extensive research in the past decades, unfortunately without any major medical breakthroughs. Due to the growing unmet medical need and the increasing evidence of a potential therapeutic role for GLP-1, we will investigate the benefits of oral semaglutide in early Alzheimer’s disease.”
On 16 December at 4 pm CET, corresponding to 10 am EST, a conference call for investors will be held where members of management will elaborate on the decision and provide a brief update on the GLP-1 R&D strategy. Investors will be able to listen in via a link on the investor section of novonordisk.com.
About Alzheimer’s disease
Alzheimer’s disease represents a rapidly growing public health concern causing significant detrimental consequences to the affected people and their families and has led to substantial and increasing global socioeconomic impact. Worldwide, 70-100 million people are estimated to have early Alzheimer’s disease (mild cognitive impairment and mild dementia stages).
About data from preclinical models, real-world evidence studies and the post-hoc analysis
Animal studies highlight the key effects of GLP-1 relevant for Alzheimer’s disease including improved memory function and reduced phospho-tau accumulation. Semaglutide has specifically been shown to reduce measures of neuro-inflammation which may affect cognition and function.
Further, real-world evidence from two Danish nationwide registries, the US Truven claims database and the US FDA FAERS database support a potential association between lower risk of dementia following treatment with GLP-1.
Finally, in a post-hoc analysis of data from three large cardiovascular outcomes trials conducted by Novo Nordisk (LEADER, SUSTAIN 6 and PIONEER 6), which included 15,820 patients with type 2 diabetes with median follow-up of 3.6 years, a total number of 47 people were identified with development of dementia, of which 32 were on placebo and 15 on GLP-1 (liraglutide or semaglutide). The rate of developing dementia was statistically significantly reduced by 53% in favour of GLP-1.
About oral semaglutide
Oral semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan. The approval of Rybelsus® is based on the results from 10 clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® demonstrated a safe and well-tolerated profile across the clinical trials, with the most common adverse event being mild to moderate nausea which diminished over time.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,Facebook, Twitter, LinkedIn, YouTube.
|Mette Kruse Danielsen||+45 3079 email@example.com|
|Ken Inchausti (US)||+1 609 240 firstname.lastname@example.org|
|Daniel Muusmann Bohsen||+45 3075 email@example.com|
|Valdemar Borum Svarrer||+45 3079 firstname.lastname@example.org|
|Ann Søndermølle Rendbæk||+45 3075 email@example.com|
|Mark Joseph Root||+45 3079 firstname.lastname@example.org|
|Kristoffer Due Berg (US)||+1 609 235 email@example.com|
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER18.1.2021 16:20:00 CET | Press release
* Bid procedure, 2021-01-20CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-07-20 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-01-11 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-01-20Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the
Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.)18.1.2021 15:20:00 CET | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 18 January 2021 at 4:20 pm Disclosure Under Chapter 9 Section 5 of the Securities Market Act (BlackRock, Inc.) Sampo plc (business code 0142213-3) has received a disclosure under Chapter 9, Section 5 of the Securities Markets Act, according to which the total number of Sampo A shares (ISIN: FI009003305) owned directly, indirectly or through financial instruments by BlackRock, Inc. (USA tax ID 32-0174421) and its funds increased on 15 January 2021 above five (5) per cent of Sampo plc's total stock. Sampo's share capital comprises 555,351,850 shares, of which 554,151,850 are A shares and 1,200,000 are B shares. Each A share entitles its holder to one (1) vote and each B share to five (5) votes. Thus, the total number of votes is 560,151,850. Total positions of BlackRock, Inc and its funds subject to the notification: % of shares and voting rights (total of A)% of shares and voting rights through financial instruments (total of B)Total of both in % (A+B)Re
Suominen Corporation: Notification of change in holdings according to chapter 9, section 10 of the Securities Market Act18.1.2021 15:00:00 CET | Press release
Suominen Corporation, stock exchange release on January 18, 2021 at 4 p.m. (EET). Suominen Corporation has received a notification on January 18, 2021 referred to Chapter 9, Section 5 and 6 of the Securities Market Act. According to the notification, the shareholding of Elo Mutual Pension Insurance Company in Suominen Corporation has fallen under the 5% flagging threshold. Total positions of person subject to the notification obligation: % of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in % (7.A + 7.B)Total number of shares and voting rights of the issuerResulting situation on the date on which threshold was crossed or reached4.33%4.33%58,259,219Position of previous notification (if applicable)5.19%5.19% Notified details of the resulting situation on the date on which the threshold was crossed or reached: A: Shares and voting rightsClass/type of sharesNumber of shares and voting rights% of shares and vot
Taaleri SolarWind II fund invests in two ready-to-build wind farms in Poland with a combined capacity of 51.4 MW18.1.2021 14:30:00 CET | Press release
TAALERI PLC PRESS RELEASE 18 JANUARY 2021 AT 15.30 (EET) Taaleri SolarWind II fund invests in two ready-to-build wind farms in Poland with a combined capacity of 51.4 MW The Taaleri SolarWind II fund has, together with Masdar, one of the world’s leading renewable energy companies, acquired 100% ownership of the Mlawa and Grajewo wind farms. The wind farms are located in Northern Poland in the counties of Mazowieckie and Podlaskie. Masdar is Taaleri Energia’s joint venture partner in the CEE region. Construction works on both wind farms started in June 2020. With 24 Vestas V110 turbines, the wind farms will have a combined installed capacity of 51.4 MW and the combined annual production of electricity will be approximately 192 GWh. The wind farms will produce enough electricity to supply around 90000 households and will offset the equivalent of 146,000 tonnes of carbon dioxide during each year of operation. The projects were developed by Vestas together with V-Ridium Power Services. V-R
Elon och Elon Ljud & Bild bäst i branschen på medkänsla18.1.2021 13:00:00 CET | Pressemelding
Elon och Elon Ljud & Bild bäst i branschen på medkänsla Elon får högsta resultat i kategorin hemelektronik i Empati Grand Prix 2021. På den digitala galan presenterades resultatet där över 3000 svenskar varit med och röstat fram handelns mest empatiska företag. 2019 inledde vitvarukedjan Elon och hemelektronikkedjan Elon Ljud & Bild ett samarbete för att tillsammans bli den ledande fackhandelskedjan inom både hemelektronik och vitvaror på marknaden. Nu visar årets undersökning att de båda kedjorna gemensamt har ett starkt varumärke och är bäst i klassen på att förstå och känna empati. - Det är oerhört glädjande att se resultaten i undersökningen. Våra handlare runt om i landet gör ett fantastiskt arbete där service prioriteras och kunden alltid står i centrum. Det är såklart med stolthet som man tar del av resultaten i Empati Grand Prix, säger Martin Torstensson, kedjechef för Elon Ljud & Bild. Priset Empati Grand Prix arrangeras av Index House tillsammans med kommunikationsbyrån Pool.
Avance Gas enter into contracts for two dual fuel VLGC newbuildings with DSME18.1.2021 11:05:00 CET | Press release
Avance Gas Holding Ltd (OSE: "AGAS", or the "Company") today announces that it has entered into shipbuilding contracts for two 91,000 CBM, LPG Dual-Fuel VLGCs with Daewoo Shipbuilding and Marine Engineering (DSME) in South Korea, for delivery Q4 2022 and Q1 2023. The investment enhances the green profile of the Avance Gas fleet, allowing the company to take another important step towards de-carbonisation while contributing to a greener shipping industry and achieving the targeted 40% reduction in emissions by 2030. The new vessels are capable of burning LPG, have larger intake and lower daily consumption. They will also be fitted with shaft generator further enhancing emissions reduction for an even greater greener profile. The outlook for the freight market remains healthy, supported by continued strong US LPG exports and growing Asian demand. The price and terms are attractive and we expect that the vessels will also secure attractive financing in line with their environmentally frie
SEK CREDIT OPERATION ANNOUNCEMENT18.1.2021 10:30:00 CET | Press release
Bid date, 2021-01-18Auction date2021-01-18Settlement date2021-01-18Maturity Date2021-04-19Term13 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to firstname.lastname@example.orgOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-01-18 Bid date, 2021-01-18Auction date2021-01-18Settlement date2021-01-18Maturity Date2021-07-19Term26 weeksInterest rateThe Riksbank´s applicable repo rateBid times11.00-11.30 (CET/CEST) on the Bid dateConfirmation of bids to email@example.comOffered volumeUnlimitedThe lowest accepted bid volume50 million SEKMaximum number of bids1Allocation Time11.45 (CET/CEST) on the Bid date Stockholm, 2021-01-18 This is a translation of the Swedish version published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language v